AS703569 Phase I in Patients With Solid Tumours
This is a Phase I trial. Some specific protocol information is proprietary and is not publicly available at this time. Full information will be provided to trial participants.
Solid Tumors
DRUG: AS703569|DRUG: AS703569|DRUG: AS703569
Number and proportion of subjects experiencing: at least a Dose-Limiting Toxicity (DLT) in each cohort during the first cycle., Undefined
Plasma and urine PK parameters of AS703569, genetic markers and potential markers of clinical and biological response., Undefined|Number and proportion of subjects with Progressive Disease as assessed at the end of every other cycle., Undefined
This is a Phase I trial. Some specific protocol information is proprietary and is not publicly available at this time. Full information will be provided to trial participants.